论文部分内容阅读
肿瘤化疗的主要限制因素是有效地杀伤肿瘤细胞的药物往往对迅速增殖的正常细胞也有毒性。增进化疗药选择性的一种方式是用抗体作为药物的特异性载体,直接作用肿瘤细胞,但它只能一次性使用,并且可引起患者的异体蛋白的过敏反应。然而利用甲胎蛋白(AFP)与多烯脂肪酸强烈结合作为药物载体用于肝癌化疗已引起人们的注意。研究发现,柔红霉素的多烯脂肪酸复合物可有效的抑制大鼠肝癌细胞的生长。本文观察了DM-C20∶0复合物治疗大鼠接种能产生ATP 的AH66肝癌细胞株的效果,以及此药在体外血浆和肝细胞匀浆混合后的化学性质。
The main limiting factor in cancer chemotherapy is that drugs that effectively kill tumor cells are often also toxic to rapidly proliferating normal cells. One way to enhance the chemotherapeutic drug selectivity is to use the antibody as a drug specific carrier that acts directly on the tumor cells but it can only be used once and can cause an allergic reaction to the patient’s allogeneic protein. However, the use of AFP and polyene fatty acids as a drug carrier strongly combined for liver cancer chemotherapy has drawn people’s attention. The study found that daunorubicin polyene fatty acid complex can effectively inhibit the growth of rat hepatoma cells. In this paper, the effect of DM-C20: 0 complex on the inoculation of ATP-producing AH66 hepatocarcinoma cell line was observed and the chemical properties of this drug after mixing in vitro plasma and hepatocyte homogenate were observed.